

**ondine**



**For Immediate Release**

## **Ondine Receives a Health Canada License for the use of Periowave™ to treat Gingivitis**

**Vancouver, Canada – March 19, 2007** - Ondine Biopharma Corporation (TSX: OBP; AIM: OBP) today announced that it has received a Health Canada license for use of the Periowave™ Photodisinfection system for the treatment of gingivitis. Gingivitis is an inflammation of the gums that affects up to 80% of the population, and can lead to serious forms of gum disease including periodontitis.

“Periowave™ destroys bacteria that can attach to tooth and root surfaces, resulting in an effective and painless new approach to the treatment of gingivitis,” said Carolyn Cross, CEO and president of Ondine Biopharma. “This additional indication represents an opportunity for clinicians to treat gum disease at an early stage. Nine out of ten Canadians will experience an episode of gingivitis at least once in their lives. Early treatment can inhibit progression of gum disease and the resulting systemic effects such as diabetes, stroke, and heart disease.”

### **About Gingivitis:**

Gingivitis is one of the most common forms of gum disease. Gingivitis is an inflammatory condition that often results in swollen, red, or bleeding gums. Scientists believe that plaque-forming bacteria living in the mouth and on tooth surfaces are the primary cause of gingivitis. Reduction of plaque bacteria can decrease inflammation and thereby cause a reduction in the gingivitis index. Left untreated, gingivitis can evolve into periodontitis, a condition which can result in loss of teeth and the supporting bone, and is closely correlated to the development of serious systemic disorders.

### **About Periowave™ and Photodisinfection (PDD):**

Periowave™ is a Photodisinfection system developed by Ondine that utilizes low-intensity lasers and wavelength-specific, light-activated compounds to specifically target and destroy microbial pathogens and reduce the symptoms of disease. The compounds are generally topically applied and one or more lasers are used to activate the compounds and complete the disinfection. The Photodisinfection technologies were developed by Professor Michael Wilson and colleagues at the Eastman Dental Institute, University College London, and licensed to Ondine by UCL Biomedica PLC, University College London. Additional information about Periowave™ is available at [www.periowave.com](http://www.periowave.com).

**About Ondine Biopharma Corporation:**

Ondine is developing non-antibiotic therapies for the treatment of a broad spectrum of bacterial, fungal and viral infections. The Company is focused on creating and commercializing leading-edge products utilizing its patented light-activated technology. Photodisinfection provides broad-spectrum antimicrobial efficacy without encouraging the formation and spread of antibiotic resistance.

The Company is headquartered in Vancouver, British Columbia, Canada, with a research laboratory in Redmond, Washington, USA, a sales and marketing subsidiary in York, Pennsylvania, and an international office in St Michael, Barbados. For additional information, please visit the Company's website at: [www.ondinebiopharma.com](http://www.ondinebiopharma.com).

*Forward-Looking Statements:*

*Certain statements contained in this release containing words like "believe", "intend", "may", "expect" and other similar expressions, are forward-looking statements that involve a number of risks and uncertainties. Factors that could cause actual results to differ materially from those projected in the Company's forward-looking statements include the following: market acceptance of our technologies and products; our ability to obtain financing; our financial and technical resources relative to those of our competitors; our ability to keep up with rapid technological change; government regulation of our technologies; our ability to enforce our intellectual property rights and protect our proprietary technologies; the ability to obtain and develop partnership opportunities; the timing of commercial product launches; the ability to achieve key technical milestones in key products and other risk factors identified from time to time in the Company's filings.*

**For further information please contact:**

Carolyn Cross	Christina Bessant
President and Chief Executive Officer	Investor Relations
Ondine Biopharma Corporation	The Equicom Group Inc.
(604) 669-0555	(416) 815-0700 ext. 269
ccross@ondinebiopharma.com	cbessant@equicomgroup.com